New IV drug shows promise for postpartum depression

NCT ID NCT02942017

Completed Symptom relief Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a drug called SAGE-547, given as an IV infusion over 60 hours, to see if it could reduce symptoms of postpartum depression in women. 108 women with moderate to severe depression after childbirth took part. The goal was to measure changes in depression scores compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAGE-547 (a drug given by IV infusion)
What this could lead to: If successful, this could provide a fast-acting treatment option for women suffering from postpartum depression, reducing symptoms within days.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to all women. The drug is given intravenously, which requires medical supervision, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postpartum depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTPARTUM DEPRESSION

Contacts and locations

Locations

Sage Investigational Site

Chandler, Arizona, 85226, United States
Sage Investigational Site

Rogers, Arkansas, 72758, United States
Sage Investigational Site

Lemon Grove, California, 91945, United States
Sage Investigational Site

Orange, California, 92868, United States
Sage Investigational Site

Ventura, California, 93003, United States
Sage Investigational Site

Gainesville, Florida, 32607, United States
Sage Investigational Site

Miami, Florida, 33147, United States
Sage Investigational Site

Miramar, Florida, 33027, United States
Sage Investigational Site

Orlando, Florida, 32807, United States
Sage Investigational Site

Pensacola, Florida, 32502, United States
Sage Investigational Site

Pinellas Park, Florida, 33782, United States
Sage Investigational Site

Atlanta, Georgia, 30331, United States
Sage Investigational Site

Hoffman Estates, Illinois, 60169, United States
Sage Investigational Site

Wichita, Kansas, 67226, United States
Sage Investigational Site

Edgewood, Kentucky, 41017, United States
Sage Investigational Site

Owensboro, Kentucky, 42303, United States
Sage Investigational Site

Boston, Massachusetts, 02114, United States
Sage Investigational Site

Flowood, Mississippi, 39232, United States
Sage Investigational Site

Marlton, New Jersey, 08053, United States
Sage Investigational Site

Glen Oaks, New York, 11004, United States
Sage Investigational Site

Chapel Hill, North Carolina, 27514, United States
Sage Investigational Site

Charlotte, North Carolina, 28211, United States
Sage Investigational Site

Raleigh, North Carolina, 27612, United States
Sage Investigational Site

Columbus, Ohio, 43210, United States
Sage Investigational Site

Dayton, Ohio, 45417, United States
Sage Investigational Site

Philadelphia, Pennsylvania, 19104, United States
Sage Investigational Site

Baytown, Texas, 77521, United States
Sage Investigational Site

Houston, Texas, 77030, United States
Sage Investigational Site

Houston, Texas, 77058, United States
Sage Investigational Site

Richardson, Texas, 75080, United States
Sage Investigational Site

San Antonio, Texas, 78229, United States
Sage Investigational Site

Orem, Utah, 84058, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.